Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia (vol 39, pg 57, 2021)

被引：0
|
作者：
DiNardo, C. D.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 04期
关键词：
D O I：
10.1200/JCO.20.03658
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：341 / 341
页数：1
相关论文
共 50 条
  • [1] Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
    DiNardo, Courtney D.
    Stein, Anthony S.
    Stein, Eytan M.
    Fathi, Amir T.
    Frankfurt, Olga
    Schuh, Andre C.
    Dohner, Hartmut
    Martinelli, Giovanni
    Patel, Prapti A.
    Raffoux, Emmanuel
    Tan, Peter
    Zeidan, Amer M.
    de Botton, Stephane
    Kantarjian, Hagop M.
    Stone, Richard M.
    Frattini, Mark G.
    Lersch, Frederik
    Gong, Jing
    Gianolio, Diego A.
    Zhang, Vickie
    Franovic, Aleksandra
    Fan, Bin
    Goldwasser, Meredith
    Daigle, Scott
    Choe, Sung
    Wu, Bin
    Winkler, Thomas
    Vyas, Paresh
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (01) : 57 - +
  • [2] Mutant Isocitrate Dehydrogenase Inhibitors, Enasidenib or Ivosidenib, in Combination With Azacitidine: Preliminary Results of a Phase 1b/2 Study in Patients With Newly Diagnosed Acute Myeloid Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 9 - 11
  • [3] Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
    DiNardo, Courtney D.
    Stein, Anthony S.
    Fathi, Amir T.
    Montesinos, Pau
    Odenike, Olatoyosi
    Kantarjian, Hagop M.
    Stone, Richard M.
    Koralek, Daniel O.
    Van Oostendorp, Jason
    Gong, Jing
    Gupta, Ira
    Vyas, Paresh
    BLOOD, 2017, 130
  • [4] Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).
    Dinardo, Courtney Denton
    Stein, Anthony Selwyn
    Stein, Eytan M.
    Fathi, Amir Tahmasb
    Frankfurt, Olga
    Schuh, Andre C.
    Martinelli, Giovanni
    Patel, Prapti Arvind
    Raffoux, Emmanuel
    Tan, Peter
    Zeidan, Amer Methqal
    de Botton, Stephane
    Kantarjian, Hagop M.
    Stone, Richard M.
    Lam, Du Hung
    Gong, Jing
    Zhang, Vickie
    Winkler, Thomas
    Wu, Bin
    Vyas, Paresh
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
    DiNardo, Courtney D.
    Stein, Anthony S.
    Stein, Eytan M.
    Fathi, Amir T.
    Frankfurt, Olga
    Schuh, Andre C.
    Doehner, Hartmut
    Martinelli, Giovanni
    Raffoux, Emmanuel
    Tan, Peter
    Zeidan, Amer
    de Botton, Stephane
    Kantarjian, Hagop M.
    Stone, Richard M.
    Lam, Du
    Wang, Xiwei
    Gong, Jing
    Kapsalis, Stephanie M.
    Hickman, Denice
    Zhang, Vickie
    Winkler, Thomas
    Daigle, Scott
    Vyas, Paresh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S217 - S218
  • [6] Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
    DiNardo, C.
    Stein, A.
    Stein, E.
    Fathi, A.
    Frankfurt, O.
    Schuh, A.
    Doehner, H.
    Martinelli, G.
    Patel, P.
    Raffoux, E.
    Tan, P.
    Zeidan, A.
    de Botton, S.
    Kantarjian, H.
    Stone, R.
    Lam, D.
    Wang, X.
    Gong, J.
    Kapsalis, S.
    Hickman, D.
    Zhang, V.
    Winkler, T.
    Wu, B.
    Vyas, P.
    ANNALS OF HEMATOLOGY, 2019, 98 : S40 - S41
  • [7] FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation
    Woods, Ashley
    Norsworthy, Kelly J.
    Wang, Xin
    Vallejo, Jonathon
    Chow, Edwin Chiu Yuen
    Li, Ruo-Jing
    Sun, Jielin
    Charlab, Rosane
    Jiang, Xiling
    Pazdur, Richard
    Theoret, Marc R.
    de Claro, R. Angelo
    CLINICAL CANCER RESEARCH, 2024, 30 (07) : 1226 - 1231
  • [8] Molecular Characterization of Clinical Response and Relapse in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine
    Daigle, Scott R.
    Choe, Sung
    DiNardo, Courtney D.
    Stein, Anthony S.
    Stein, Eytan M.
    Fathi, Amir T.
    Frankfurt, Olga
    Schuh, Andre C.
    Dohner, Hartmut
    Martinelli, Giovanni
    Patel, Prapti A.
    Raffoux, Emmanuel
    Tan, Peter
    Zeidan, Amer M.
    De Botton, Stephane
    Stone, Richard M.
    Frattini, Mark
    Franovic, Aleksandra
    Xu, Emily
    Winkler, Thomas
    Wu, Bin
    Vyas, Paresh
    BLOOD, 2020, 136
  • [9] Isocitrate Dehydrogenase 1 Mutation and Ivosidenib in Patients With Acute Myeloid Leukemia: A Comprehensive Review
    Tangella, Adarsh Vardhan
    Gajre, Ashwin
    Kantheti, Vivek Varma
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [10] Hematologic improvements with ivosidenib plus azacitidine compared to placebo plus azacitidine in patients with newly diagnosed acute myeloid leukemia.
    Dohner, Hartmut
    Montesinos, Pau
    Polo, Susana Vives
    Zarzycka, Ewa
    Wang, Jianxiang
    Bertani, Giambattista
    Heuser, Michael
    Calado, Rodrigo T.
    Schuh, Andre C.
    Yeh, Su-Peng
    Burguera, Adolfo de la Fuente
    Cerchione, Claudio
    Daigle, Scott
    Hui, Jianan
    Pandya, Shuchi Sumant
    Gianolio, Diego A.
    Recher, Christian
    De Botton, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345